AUTHOR=Wei Chao-Gang , Zhang Rui , Wei Lan-Yi , Pan Peng , Zu He , Liu Ya-Zhen , Wang Yong , Shen Jun-Kang 

TITLE=Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

JOURNAL=Frontiers in Bioengineering and Biotechnology

VOLUME=10

YEAR=2022

URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.1078342

DOI=10.3389/fbioe.2022.1078342

ISSN=2296-4185

ABSTRACT=<p><bold>Introduction:</bold> Erythropoietin producing hepatocyte receptor A2 (<italic>EphA2</italic>) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation. Based on its high expression in castration-resistant prostate cancer (CRPC), we herein develop a CRISPR-Cas9-based genome-editing nanomedicine to target erythropoietin producing hepatocyte receptor A2 for the treatment of castration-resistant prostate cancer.</p><p><bold>Methods:</bold> To this end, TAT was designed to stabilize the distribution of calcium, and then bound to ribonucleoprotein (RNP) to form nanoparticles RNP@CaP-TAT.</p><p><bold>Results:</bold> This nanoparticle has a simple synthesis process with good biocompatible, to achieve the knockout of tumor cells (PC-3) targeting erythropoietin producing hepatocyte receptor A2 gene and to effectively suppress the migration of tumor cells.</p><p><bold>Discussion:</bold> This delivery genome editing system provides a promising gene therapy strategy for the treatment of castration-resistant prostate cancer, showing good potential against castration-resistant prostate cancer tumor metastasis. In addition, it can be extended to other types of cancer with highly heterogeneous gene expression.</p>